Optimizing dose selection using population PK/FD modeling and simulation for the cholesteryl ester transfer protein (CETP) inhibitor MK-0859 in healthy subjects

8

  • Bergman, A.
  • Dykstra, K.
  • Al-Huniti, N.
  • Fallon, M.
  • Lute, R.
  • Chavez-Eng, C.
  • Jin, B.
  • Hartford, A.
  • Cote, J.
  • Hilliard, D.
  • Laethem, T.
  • Van Hoydonck, P.
  • Snyder, K.
  • Van Dyck, K.
  • Stone, J.
  • Lasseter, K. C.
  • Van Bortel, L.
  • Wagner, J.
  • Krishna, R.

  • 1 Merck & Co, Inc; 2Pharsight Corporation; 3PharmaNet Development Group, Miami, FL; University Hospital; 4Ghent University Hospital

The Journal of Clinical Pharmacology 48(9):p 1100, September 2008.
Copyright © 2008 American College of Clinical Pharmacology